Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piclidenoson in Lowe Syndrome
NCT07410455Phase 2Not yet recruiting
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of piclidenoson in Lowe syndrome, sponsored by Can-Fite BioPharma Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
piclidenoson
03
Conditions
Lowe syndrome
Beyond the preview
Go deeper on NCT07410455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410455.